Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Shaking Palsy
- Muhammad Ali
- Where are we at the moment?
- Drugs that manipulate dopamine metabolism
- Dopamine metabolism and drugs (schematic)
- 4 big questions
- Publications on Parkinson’s disease (PD)
- Genome-wide association and PD
- Genetic interplay between PD and other disorders
- Pinpointing specific genes relevant to PD
- TMEM175 and Parkinson’s disease
- TMEM175 structural studies
- a-synuclein & neurodegenerative disease
- Susan Lindquist
- Using genome-scale networks for PD research
- From yeast to neurons
- Parkinson’s as a polygenic disease
- PINK1 and Parkin (1)
- PINK1 and Parkin (2)
- Parkinson’s disease and gut microbiota (1)
- Parkinson’s disease and gut microbiota (2)
- Parkinson’s disease and protein aggregation
- The structure of aggregates
- Different cell types in Parkinson’s disease
- Role of immune system in Parkinson’s disease
- Novel treatments and drugs for PD
- Clinical Trials
- Potential drug target in Parkinson’s disease
- Structural model of LRRK2
- Kinase inhibitors of LRRK2
- Functional rescue
- Ambroxol: potential therapeutic compound
- Promising results in clinical trial of Exanitide
- Prediction of Parkinson’s disease
- Parkinson’s at 200 years: summary
Topics Covered
- Shaking palsy: first milestone in Parkinson’s disease
- Key areas of research, unanswered questions and unmet needs
- Drugs that manipulate dopamine metabolism
- Pinpointing specific genes relevant to Parkinson’s disease
- Parkinson’s and gut microbiota
- Parkinson’s and protein aggregation
- Role of immune system in Parkinson’s disease
- Novel/Future treatments and drugs
- Prediction of Parkinson’s disease
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Lewis, P.A. (2017, August 31). Parkinson’s at 200 years: an update on Parkinson’s research in 2017 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/GDSE2579.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Patrick A. Lewis has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, my name is Patrick Lewis,
and I'm an Associate Professor in The School of Pharmacy at the University of Reading.
In this talk, I'll be providing a review of Parkinson's Research in 2016 and 2017,
moving towards the 200th anniversary of
James Parkinson's publication of his essay on the Shaking Palsy.
0:24
2017 marks an important milestone in Parkinson's research as it
has been 200 years since the publication of the Shaking Palsy by James Parkinson,
which first described the disease that we now know as Parkinson's Disease;
And shown here, on the right hand of the slide is an image of a Parkinson's patient,
one of the first images we have of such a patient,
drawn by Jean-Martin Charcot working in Paris,
who was one of the key people in giving
the disease Parkinson's name in honour of his contribution.
And we have made a huge amount of progress in those 200 years.
1:06
Over the past year,
we have seen a number of public events that
have also brought Parkinson's to the public attention.
Most notably, the death of Muhammad Ali who suffered from
Parkinson's for many years before his death in 2016.
And so 2017 is a good period in which to
reflect on our progress and understanding of Parkinson's disease.
1:30
We actually know quite a lot about the underlying pathology of Parkinson's disease.
This is an image of the human mid-brain
showing the damage which is inflicted in Parkinson's.
In particular, the region of the brain called the substantia nigra,
which is highlighted here in a Parkinson's patient,
and a non-Parkinson's patient above.
The loss of the pigmentation in this area is due to the huge loss of dopaminergic neuron,
and it is this which underpins many of the symptoms which define Parkinson's disease.